


Applicants: Cornelia J. Forster et al.
Application No.: 10/632,340

AMENDMENTS TO THE CLAIMS

Please replace all prior versions and listings of claims with the amended claims as follows:

1. (Currently amended) A compound of formula I:



I

or a pharmaceutically acceptable salt thereof, wherein:

W is nitrogen;

R¹ is selected from hydrogen or fluorine; and

R² is ~~ethyl, cyclopropyl, tert-butyl, or isopropyl~~ a C₁₋₄ aliphatic group, optionally substituted with N(R³)₂ or a 5-6 membered saturated ring having 1-2 heteroatoms independently selected from nitrogen, oxygen, or sulfur, wherein:

each R² is independently selected from hydrogen or a C₁₋₃ aliphatic group optionally substituted with OH, N(R³)₂, or a 5-6 membered saturated ring having 1-2 heteroatoms independently selected from nitrogen, oxygen, or sulfur; and wherein:

each R³ is independently selected from hydrogen or a C₁₋₃ aliphatic group.

2. (Canceled)

Applicants: Cornelia J. Forster et al.
Application No.: 10/632,340

3. (Currently amended) The compound of claim 2, wherein R^y is selected from methyl, ethyl, cyclopropyl, *tert*-butyl, or isopropyl.

4. (Currently amended) The compound according to claim 3, wherein R^y is selected from methyl, cyclopropyl, or *tert*-butyl.


5-6. (Canceled)

7. (Original) The compound according to claim 1, wherein R¹ is hydrogen.


8. (Original) The compound according to claim 1, wherein R¹ is fluorine.

9-11. (Canceled)


12. (Currently amended) A compound selected from the group consisting of:




I-1



I-3




and I-5



I-6.


Applicants: Cornelia J. Forster et al.
Application No.: 10/632,340



I-7

I-8


I-9



I-10

I-11


I-12



I-13

I-14

I-15



I-16

I-17

and I-18.

Applicants: Cornelia J. Forster et al.
Application No.: 10/632,340

13. (Previously presented) A pharmaceutically acceptable composition comprising a compound according to claim 1, and a pharmaceutically acceptable carrier, adjuvant, or vehicle.

14. (Previously presented) The composition according to claim 13, additionally comprising an additional therapeutic agent selected from an agent for treating stroke, an antidepressant, an anti-psychotic agent, or an agent for treating diabetes.

15-17. (Canceled)

18. (Previously presented) A method of treating a disease, disorder, or condition selected from diabetes, schizophrenia, anxiety, bipolar disorder, stroke, in a patient in need thereof, comprising administering and effective amount of the composition according to claim 13 to said patient.

19-22. (Canceled)

23. (Previously presented) The method according to claim 18, comprising the additional step of administering to said patient an additional therapeutic agent selected from an agent for treating stroke, an antidepressant, an anti-psychotic agent, or an agent for treating diabetes, wherein:

said additional therapeutic agent is appropriate for the disease being treated;
and

said additional therapeutic agent is administered together with said composition as a single dosage form or separately from said composition as part of a multiple dosage form.

24. (Currently amended) The compound of claim 12, selected from the group consisting of I-1, I-3, I-5, I-6, and I-7.

Applicants: Cornelia J. Forster et al.
Application No.: 10/632,340

25. (New) The compound of claim 1, wherein R^y is a C_{1-4} aliphatic group.

26. (New) The compound according to claim 1, wherein R^y is a C_{1-4} aliphatic group substituted with a 6-membered saturated ring having 1-2 heteroatoms independently selected from nitrogen, oxygen, or sulfur.

27. (New) The compound according to claim 9, wherein R^y is a C_{1-4} aliphatic group substituted with a morpholinyl, piperidinyl, or piperazinyl ring

28. (New) The compound according to claim 1, wherein R^y is a C_{1-4} aliphatic group substituted with $N(R^2)_2$.